{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:54:00Z","timestamp":1761310440610,"version":"3.33.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.euroneuro.2007.07.009","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T11:26:49Z","timestamp":1188991609000},"page":"414-421","source":"Crossref","is-referenced-by-count":62,"title":["Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine"],"prefix":"10.1016","volume":"18","author":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamaki","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2007.07.009_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2005.04.007","article-title":"Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion","volume":"26","author":"Aragon","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib2","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/mol.60.6.1414","article-title":"ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter","volume":"60","author":"Atkinson","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib3","doi-asserted-by":"crossref","first-page":"15730","DOI":"10.1073\/pnas.95.26.15730","article-title":"Modulation of N-methyl-d-aspartate receptor function by glycine transport","volume":"95","author":"Bergeron","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/cercor\/bhh147","article-title":"Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain","volume":"15","author":"Cubelos","year":"2005","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-6997(24)01382-6","article-title":"Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications","volume":"50","author":"Danysz","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib7","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.npp.1300772","article-title":"Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic","volume":"30","author":"Depoortere","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.tibs.2005.04.004","article-title":"Glycine transporters: essential regulators of neurotransmission","volume":"30","author":"Eulenberg","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/bmc.394","article-title":"Simultaneous determination of d- and l-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection","volume":"18","author":"Fukushima","year":"2004","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0896-6273(03)00672-X","article-title":"Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition","volume":"40","author":"Gomeza","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-003-1761-y","article-title":"The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications","volume":"174","author":"Harrison","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/092986706776360932","article-title":"Glycine transporter type-1 and its inhibitors","volume":"13","author":"Harsing","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib15","doi-asserted-by":"crossref","unstructured":"Hashimoto, K., 2006a. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents on CNS Drug Discovery 1, 43\u201354.","DOI":"10.2174\/157488906775245336"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib16","first-page":"3","article-title":"The NMDA receptor hypofunction for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs","volume":"4","author":"Hashimoto","year":"2006","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib17","doi-asserted-by":"crossref","unstructured":"Hashimoto, K., in press. Glycine transporter-1 inhibitors as novel therapeutic drugs for schizophrenia. CNS Agents Med. Chem. 7.","DOI":"10.2174\/187152407781669161"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib23","first-page":"81","article-title":"Candidate genes and models. Chapter 6. Neurotransmission","author":"Hashimoto","year":"2007"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1568015043357011","article-title":"Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs","volume":"4","author":"Hashimoto","year":"2004","journal-title":"Curr. Med. Chem.-CNS Agents"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-244X-5-6","article-title":"Elevated glutamine\/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients","volume":"5","author":"Hashimoto","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"Hashimoto","year":"2005","journal-title":"Curr. Psychiatry Rev."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2006.09.055","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of \u03b17 nicotinic receptors","volume":"553","author":"Hashimoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib26","first-page":"1067","article-title":"Glycine modulators in schizophrenia","volume":"3","author":"Javitt","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.yco.0000214340.14131.bd","article-title":"Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients","volume":"19","author":"Javitt","year":"2006","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.npp.1300313","article-title":"Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor\/glycine-site agonists","volume":"29","author":"Javitt","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1570159052773387","article-title":"Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia","volume":"3","author":"Kinney","year":"2005","journal-title":"Curr. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib32","doi-asserted-by":"crossref","first-page":"7586","DOI":"10.1523\/JNEUROSCI.23-20-07586.2003","article-title":"The glycine transporter type 1 inhibitor N-[3-(4\u2032-fluorophenyl)-3-(4\u2032-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior","volume":"23","author":"Kinney","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/hrp.7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1999","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2004.07.005","article-title":"Neurocognitive impairment across the lifespan in schizophrenia: an update","volume":"74","author":"Kurtz","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib35","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S0006-3223(03)00374-3","article-title":"Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor","volume":"54","author":"Le Pen","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-005-2210-x","article-title":"Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia","volume":"179","author":"Lipina","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1568007024606258","article-title":"N-methyl-d-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review","volume":"1","author":"Millan","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib39","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib40","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1098\/rstb.2003.1399","article-title":"The N-methyl d-aspartate receptor glycine site and d-serine metabolism: an evolutionary perspective","volume":"359","author":"Schell","year":"2004","journal-title":"Philos. Trans. R. Soc. Lond., B Biol. Sci."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib41","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0896-6273(92)90207-T","article-title":"Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors","volume":"8","author":"Smith","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib42","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1176\/appi.ajp.157.11.1738","article-title":"Novel neurotransmitters and their neuropsychiatric relevance","volume":"157","author":"Snyder","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/13543784.13.5.515","article-title":"The therapeutic potential of glycine transporter-1 inhibitors","volume":"13","author":"Sur","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib44","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib45","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.0402662101","article-title":"Gene knockout of glycine transporter 1: characterization of the behavioral phenotype","volume":"101","author":"Tsai","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"d-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728222.5.4.507","article-title":"Glycine transport inhibitors as potential antipsychotic drugs","volume":"5","author":"Vandenberg","year":"2001","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0031-9384(02)00936-8","article-title":"Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction","volume":"77","author":"Volk","year":"2002","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.euroneuro.2007.07.009_bib49","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.biopsych.2005.03.018","article-title":"Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels","volume":"57","author":"Yamada","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.07.009_bib50","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1523\/JNEUROSCI.5120-05.2006","article-title":"Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile","volume":"26","author":"Yee","year":"2006","journal-title":"J. Neurosci."},{"issue":"5 Pt 2","key":"10.1016\/j.euroneuro.2007.07.009_bib51","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1523\/JNEUROSCI.15-05-03952.1995","article-title":"Glycine transporters are differentially expressed among CNS cells","volume":"15","author":"Zafra","year":"1995","journal-title":"J. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X07001563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X07001563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:11:25Z","timestamp":1737407485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X07001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0924977X07001563"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2007.07.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}